Pharmacologic therapy for osteoarthritis--the era of disease modification (Q37809746)

23 August 2017

Pharmacologic therapy for osteoarthritis--the era of disease modification (English)

1 reference

23 August 2017

0 references

1 reference

David J Hunter

1

1 reference

PubMed ID

21079644

23 August 2017

language of work or name

English

0 references

publication date

16 November 2010

1 reference

Nature Reviews Rheumatology

23 August 2017

1 reference

23 August 2017

7

1 reference

23 August 2017

1

1 reference

23 August 2017

13-22

1 reference

https://scigraph.springernature.com/pub.10.1038/nrrheum.2010.178

23 August 2017

0 references

cites work

Overview of bone morphogenetic proteins

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Relation of dietary intake and serum levels of vitamin D to progression of osteoarthritis of the knee among participants in the Framingham Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Focusing osteoarthritis management on modifiable risk factors and future therapeutic prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Osteoarthritis: a problem of joint failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Collagens and cartilage matrix homeostasis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Arthritis prevalence and activity limitations in older adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Prevalence of Symptomatic Hand Osteoarthritis and Its Impact on Functional Status among the Elderly: The Framingham Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

The effects of specific medical conditions on the functional limitations of elders in the Framingham Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

An update on the pathogenesis and epidemiology of osteoarthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Risk factors for onset of osteoarthritis of the knee in older adults: a systematic review and meta-analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

A meta-analysis of the effect of neuromuscular training on the prevention of the anterior cruciate ligament injury in female athletes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Are there promising biologic therapies for osteoarthritis?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

A 51-year-old woman with shortness of breath and edema

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Radiologic markers of osteoarthritis progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Chondroprotective drugs in degenerative joint diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

How close are we to having structure-modifying drugs available?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Disease modifying osteoarthritis drugs: facing development challenges and choosing molecular targets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Prospects for disease modification in osteoarthritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the Chondromodulating Effect of Diacerein in OA of the Hip.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Osteoarthritis - an untreatable disease?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Is anterior knee pain a predisposing factor to patellofemoral osteoarthritis?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Total hip replacement due to osteoarthritis: the importance of age, obesity, and other modifiable risk factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

The impact of body mass index on later total hip arthroplasty for primary osteoarthritis: a cohort study in 1.2 million persons

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

The sources of pain in knee osteoarthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

A pathway and approach to biomarker validation and qualification for osteoarthritis clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

A users guide to measurement in medicine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Proposal for a nomenclature for magnetic resonance imaging based measures of articular cartilage in osteoarthritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

OARSI-OMERACT definition of relevant radiological progression in hip/knee osteoarthritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Imaging in osteoarthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Yet more evidence that osteoarthritis is not a cartilage disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Effect of calcitonin in early and late stages of experimentally induced osteoarthritis. A histomorphometric study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Calcitonin is involved in cartilage homeostasis: is calcitonin a treatment for OA?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Calcitonin affects both bone and cartilage: a dual action treatment for osteoarthritis?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

New pharmacologic approaches in the management of osteoarthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Calcitonin: a drug of the past or for the future? Physiologic inhibition of bone resorption while sustaining osteoclast numbers improves bone quality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Nitric oxide in inflammation and pain associated with osteoarthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

The role of nitric oxide in osteoarthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Three-dimensional structure of recombinant human osteogenic protein 1: structural paradigm for the transforming growth factor beta superfamily

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

The TGF-beta family and its composite receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Recent advances in BMP receptor signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Alterations in endogenous osteogenic protein-1 with degeneration of human articular cartilage.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Osteogenic Protein-1 inhibits matrix depletion in a hyaluronan hexasaccharide-induced model of osteoarthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Regeneration of articular cartilage chondral defects by osteogenic protein-1 (bone morphogenetic protein-7) in sheep

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Repair of articular cartilage defects with osteogenic protein-1 (BMP-7) in dogs.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

The effect of recombinant human bone morphogenetic protein-2 (rhBMP-2) on the healing of full-thickness defects of articular cartilage

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Serum vitamin D levels and incident changes of radiographic hip osteoarthritis: a longitudinal study. Study of Osteoporotic Fractures Research Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Collagen hydrolysate for the treatment of osteoarthritis and other joint disorders: a review of the literature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Role of collagen hydrolysate in bone and joint disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

A randomized controlled trial on the efficacy and safety of a food ingredient, collagen hydrolysate, for improving joint comfort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Fibroblast growth factor-18 stimulates chondrogenesis and cartilage repair in a rat model of injury-induced osteoarthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Biological impact of the fibroblast growth factor family on articular cartilage and intervertebral disc homeostasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Avocado?soybean unsaponifiables (ASU) for osteoarthritis ? a systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthritis. A double blind, prospective, placebo-controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip: a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial with a six-month treatment period and a two-month

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Structural effect of avocado/soybean unsaponifiables on joint space loss in osteoarthritis of the hip

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Suppression of early experimental osteoarthritis by gene transfer of interleukin-1 receptor antagonist and interleukin-10.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Progress in the development of matrix metalloproteinase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Matrix metalloproteinases as valid clinical targets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Role of cathepsin K in normal joints and in the development of arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Binding and localization of recombinant lubricin to articular cartilage surfaces.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Change in cartilage morphometry: a sample of the progression cohort of the Osteoarthritis Initiative

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

MR imaging findings in early osteoarthritis of the knee

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Prevalence of bone attrition on knee radiographs and MRI in a community-based cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

The relationship between cartilage loss on magnetic resonance imaging and radiographic progression in men and women with knee osteoarthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Osteoarthritis of the knee after injury to the anterior cruciate ligament or meniscus: the influence of time and age.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

High prevalence of knee osteoarthritis, pain, and functional limitations in female soccer players twelve years after anterior cruciate ligament injury.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Impact of type of meniscal tear on radiographic and symptomatic knee osteoarthritis: A sixteen-year followup of meniscectomy with matched controls

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Risk factors for symptomatic knee osteoarthritis fifteen to twenty-two years after meniscectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Rotational changes at the knee after ACL injury cause cartilage thinning.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

The osteoarthritis initiative: report on the design rationale for the magnetic resonance imaging protocol for the knee

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthri

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Arthroscopic evaluation of potential structure modifying activity of hyaluronan (Hyalgan) in osteoarthritis of the knee

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.178

Prevalence and impact of chronic joint symptoms--seven states, 1996.

31 March 2020

1 reference

12 December 2020

OMERACT/OARSI initiative to define states of severity and indication for joint replacement in hip and knee osteoarthritis.

1 reference

12 December 2020

Osteogenic protein-1: biology and applications

1 reference

12 December 2020

Prevalence of disabilities and associated health conditions among adults--United States, 1999.

1 reference

12 December 2020

Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip. A prospective, multicenter, three-month, randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Arthritis prevalence and activity limitations--United States, 1990

1 reference

12 December 2020

Prevalence of knee osteoarthritis in the United States: arthritis data from the Third National Health and Nutrition Examination Survey 1991-94.

1 reference

12 December 2020

Nutrient intake and obesity in a multidisciplinary assessment of osteoarthritis

1 reference

12 December 2020

Management of common musculoskeletal problems: a survey of Ontario primary care physicians

1 reference

12 December 2020

Hip dysplasia: a significant risk factor for the development of hip osteoarthritis. A cross-sectional survey

1 reference

12 December 2020

A one-year, randomised, placebo (saline) controlled clinical trial of 500-730 kDa sodium hyaluronate (Hyalgan) on the radiological change in osteoarthritis of the knee.

1 reference

12 December 2020

Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis

1 reference

12 December 2020

Recommendations for use of selective and nonselective nonsteroidal antiinflammatory drugs: an American College of Rheumatology white paper

1 reference

12 December 2020

Avocado/soybean unsaponifiables increase aggrecan synthesis and reduce catabolic and proinflammatory mediator production by human osteoarthritic chondrocytes.

1 reference

12 December 2020

[Targeted anti-cytokine therapies for osteoarthritis]

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRRHEUM.2010.178

1 reference

23 August 2017

1 reference

PubMed ID

21079644